Inura is solving the unmet medical need of overactive bladder.
Basel, Switzerland (November 12, 2020) - Launchpad has invested in Inura AG, a pre-clinical company based in Liestal, Switzerland who is developing a solution to tackle the unmet medical need of overactive bladder.
Overactive bladder (OAB) is a severe chronic condition that can negatively impact patients’ quality of life. It is characterized by symptoms such as urgency, frequency, and incontinence when voiding urine. Moreover, patients who wake up more than two times per night to urinate are diagnosed as suffering from nocturia, which is another common symptom of OAB that disrupts the sleep cycle. As a result of chronic sleep deprivation, OAB causes fatigue, memory deficits, depression, embarrassment, increased risks of illnesses, and accidents. These conditions are highly debilitating and disturbing to the patient’s personal and social life, preventing them from going to work or performing very basic tasks such as going to the supermarket.
OAB is common, especially as you age, and affects around 15-20% of women over the age of 40. There are currently available treatments, however, these have serious side effects. Around 70-90% of patients discontinue the available treatments because of their side effects. Side effects experienced include constipation, dry mouth, and sometimes even tachycardia and palpitations.
"We are very excited to be part of the Inura family and to support their growth as they progress into their clinical trials. We are confident in the management team lead by Vanja and Rafiq and the technical support team from our partner, Hemex who is deeply experienced in the life science industry," says Andreas Derzsi, Managing Partner of Launchpad.
About Inura
Inura Medical AG is a Swiss start-up company developing an innovative patented urethral suppository for women, using an existing, approved drug with a well-known safety profile. It offers rescue therapy for a highly prevalent and disabling health disorder: overactive bladder syndrome (OAB). This product facilitates the effective penetration of drugs through the urethral mucosal lining, preventing this disease’s symptoms and reducing side effects.